Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data

Journal of Pharmaceutical Sciences

Volumn 91, Issue 9, 2002, Pages 1923-1935

  Yao, Caiping ^a   Levy, René H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug interaction; In vitro inhibition; In vitro in vivo correlation; In vivo inhibition constant

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CYTOCHROME P450; DESIPRAMINE; ERYTHROMYCIN; FLUVOXAMINE; KETOCONAZOLE; LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STIRIPENTOL; SULFAMETHIZOLE; TERFENADINE; TOLBUTAMIDE; TRIAZOLAM; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; MATHEMATICAL MODEL; MICHAELIS CONSTANT; SHORT SURVEY;

EID: 0036771085     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10179     Document Type: Short Survey

References (73)

1. Boston Collaborative Drug Surveillance. 1972. Adverse drug interactions. JAMA 220:1238-1239.
2. Borda IT, Slone D, Jick H. 1968. Assessment of adverse reactions within a drug surveillance program. JAMA 205:645-647.
3. Jankel CA, Fitterman LK. 1993. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9:51-59.
4. Karas S Jr. 1981. The potential for drug interactions. Ann Emerg Med 10:627-630.
5. Nics AS, Spielberg SP. 1996. Principles of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's: The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill. p 51.
6. Hansten PD. 2000. Clinical and pharmacoeconomic significance of metabolic drug interactions. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott-Raven Publishers, pp 715-721.
7. Kedderis GL. 1997. Pharmacokinetics of drug interactions. Adv Pharmacol 43:189-203.
8. CDER. 1997. Guidance for industry: Drug metabolism/drug interaction studies in the drug development process: Studies in vitro. US FDA.
9. CDER. 1999. Guidance for industry: In vivo drug metabolism/drug interaction studies: Study design, data analysis, and recommendations for dosing and labeling. US FDA
10. Bertrand M, Jackson P, Walther B. 2000. Rapid assessment of drug metabolism in the drug discovery process. Eur J Pharm Sci 11(Suppl 2):S61-S72.
11. Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL. 2000. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann NY Acad Sci 919:26-32.
12. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. 2001. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29:30-35.
13. Thummel KE, Kunze KL, Shen DD. 2000. Metabolically-based drug-drug interactions: Principles and mechanisms. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott-Raven Publishers, pp 3-19.
14. Segel IH. 1993. Simple inhibition systems. In: Enzyme kinetics, Chapter 3. New York: Wiley-Interscience Publication, pp 100-160.
15. Rando RR. 1977. Mechanism-based irreversible enzyme inhibitors. Methods Enzymol 46:28-41.
16. Rando RR. 1984. Mechanism-based enzyme inactivators. Pharmacol Rev 36:111-142.
17. Palfreyman MG, Bey P, Sjoerdsma A. 1987. Enzyme-activated/mechanism-based inhibitors. Essays Biochem 23:28-81.
18. Lin JH. 2000. Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331.
19. Rowland M, Matin SB. 1973. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1:553-567.
20. Shaw PN, Houston JB. 1987. Kinetics of drug metabolism inhibition: Use of metabolite concentration-time profiles. J Pharmacokinet Biopharm 15:497-510.
21. Levy RH, Trager WF. 2000. From in vitro to in vivo: An academic perspective. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott-Raven Publishers, pp 21-27.
22. Ring BJ, Wrighton SA. 2000. Industrial viewpoint: Application of in vitro drug metabolism in various phases of drug development. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott-Raven Publishers, pp 29-39.
23. Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y. 2000. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 28:475-481.
24. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. 1990. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411.
25. Miller AK, Adir J, Vestal RE. 1990. Excretion of tolbutamide metabolites in young and old subjects. Eur J Clin Pharmacol 38:523-524.
26. Kohl C, Steinkellner M. 2000. Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 28:161-168.
27. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. 1994. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227.
28. Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH. 1997. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 62:490-504.
29. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. 1998. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464.
30. Bonnabry P, Leemann T, Dayer P. 1996. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 49:305-308.
31. Skjodt NM, Davies NM. 1998. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet 34:421-428.
32. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. 1993. Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences [published erratum appears in JAMA 1993 Apr 28;269(16):2088] [see comments]. JAMA 269:1513-1518.
33. Wilkinson GR. 1987. Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.
34. Verbeeck RK, Wallace SM. 1994. Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance? Arzneimittelforschung 44:683-685.
35. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. 1994. Inhibitors of alprazolam metabolism in vitro: Effect of serotoninreuptake -inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.
36. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. 1992. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52:479-486.
37. Schmider J, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ. 1999. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 31:545-560.
38. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. 1996. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo [see comments]. J Clin Psychopharmacol 16:104-112.
39. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. 1996. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
40. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. 1994. Inhibition of desipramine hydroxylation in vitro by serotoninreuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
41. Larsen JT, Hansen LL, Spigset O, Brosen K. 1999. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 55:375-382.
42. Mayhew BS, Jones DR, Hall SD. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
43. Takedomi S, Matsuo H, Yamano K, Yamamoto K, Iga T, Sawada Y. 1998. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab Dispos 26:318-323.
44. Yamano K, Yamamoto K, Kotaki H, Sawada Y, Iga T. 1999. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395-402.
45. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, Iga T. 2000. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118-1126.
46. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T. 2001. Prediction of midazolam-cyp3a inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 29:443-452.
47. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
48. Maenpaa J, Hall SD, Ring BJ, Strom SC, Wrighton SA. 1998. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137-155.
49. Jean P, Lopez-Garcia P, Dansette P, Mansuy D, Goldstein JL. 1996. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur J Biochem 241:797-804.
50. Bournique B, Petry M, Gousset G. 1999. Usefulness of statistic experimental designs in enzymology: Example with recombinant hCYP3A4 and 1A2. Anal Biochem 276:18-26.
51. Ludden LK, Ludden TM, Collins JM, Pentikis HS, Strong JM. 1997. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: Implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
52. Obach RS. 1996. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations [letter]. Drug Metab Dispos 24:1047-1049.
53. McLure JA, Miners JO, Birkett DJ. 2000. Non-specific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
54. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
55. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
56. Lin JH. 1998. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202-1212.
57. Baba T, Toucji A, Yamaguchi Y, Ito K, Yamazoe Y, Sugiyama Y, Ohno Y. 2000. Can in vitro metabolism and enzyme inhibition be explained by unbound drug concentration? Presented at the International Society for the Study of Xenobiotics Meeting, Indianapolis, abstract 171.
58. Qiu W, Kunze KL, Mather GG, Black C, Levy RH. 2000. Phenytoin and tolbutamide metabolism in human liver microsomes: Complex effects of albumin on P450 activity. Presented at the International Society for the Study of Xenobiotics Meeting, Indianapolis, abstract 172.
59. Kunze KL, Trager WF. 1996. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 24:429-435.
60. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-412.
61. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
62. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. 1994. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
63. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. 2000. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 17:419-426.
64. Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. 2000. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab Dispos 28:467-474.
65. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. 1999. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
66. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. 2000. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
67. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. 2000. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366.
68. Houston JB, Kenworthy KE. 2000. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
69. Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE. 2000. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm Res 17:299-305.
70. Flexner C. 2000. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 40:649-674.
71. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
72. Hsu A, Granneman GR, Bertz RJ. 1998. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291.
73. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, Dayer P. 1999. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 55:559-565.